Tolfenamic acid enhances pancreatic cancer cell and tumor response to radiation therapy by inhibiting survivin protein expression

Molecular Cancer Therapeutics

Volumn 8, Issue 3, 2009, Pages 533-542

  Konduri, Santhi ^a   Colon, Jimmie ^a   Baker, Cheryl H ^a,b   Safe, Stephen ^c   Abbruzzese, James L ^d   Abudayyeh, Ala ^a,e   Basha, Md Riyaz ^a   Abdelrahim, Maen ^a,b,f  

^a UNIVERSITY OF CENTRAL FLORIDA   (United States)

^b UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE   (United States)

^c TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

^f M D ANDERSON CANCER CENTER ORLANDO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; SURVIVIN; TOLFENAMIC ACID; TRANSCRIPTION FACTOR SP; ANTHRANILIC ACID DERIVATIVE; BIRC5 PROTEIN, HUMAN; MICROTUBULE ASSOCIATED PROTEIN; RADIOSENSITIZING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER RADIOTHERAPY; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFICACY; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MONOTHERAPY; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RADIATION RESPONSE; RADIOSENSITIVITY; RADIOSENSITIZATION; ADENOCARCINOMA; ANIMAL; DOWN REGULATION; DRUG EFFECT; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; NUDE MOUSE; PANCREAS TUMOR; PATHOLOGY; RADIATION DOSE; RADIATION EXPOSURE; TUMOR CELL CULTURE;

ADENOCARCINOMA; ANIMALS; ANTHRANILIC ACIDS; APOPTOSIS; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; MICE, NUDE; MICROTUBULE-ASSOCIATED PROTEINS; PANCREATIC NEOPLASMS; PROMOTER REGIONS, GENETIC; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 66449110010     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0405     Document Type: Article

References (43)

1. Altieri DC. The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol Med 2001;7:542-547 (Pubitemid 33127139)
2. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997;3:917-921 (Pubitemid 27353455)
3. Adida C, Berrebi D, Peuchmaur M, Reyes-Mugica M, Altieri DC. Antiapoptosis gene, survivin, and prognosis ofneuroblastoma . Lancet 1998;351:882-883 (Pubitemid 28121185)
4. Satoh K, Kaneko K, Hirota M, Masamune A, Satoh A, Shimosegawa T. Expression ofsurvivin is correlated with cancer cell apoptosis and is involved in the development ofhu man pancreatic duct cell tumors. Cancer 2001;92:271-278 (Pubitemid 32664432)
5. Sarela AI, Verbeke CS, Ramsdale J, Davies CL, Markham AF, Guillou PJ. Expression ofsurvivin, a novel inhibitor ofapoptosis and cell cycle regulatory protein, in pancreatic adenocarcinoma. Br J Cancer 2002;86:886-892 (Pubitemid 34271023)
6. Kami K, Doi R, Koizumi M, et al. Survivin expression is a prognostic marker in pancreatic cancer patients. Surgery 2004;136:443-448 (Pubitemid 39037686)
7. Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer 2003;3:46-54. (Pubitemid 37328886)
8. Stauber RH, Mann W, Knauer SK. Nuclear and cytoplasmic survivin: molecular mechanism, prognostic, and therapeutic potential. Cancer Res 2007;67:5999-6002. (Pubitemid 47037475)
9. Rodel F, Hoffmann J, Grabenbauer GG, et al. High survivin expression is associated with reduced apoptosis in rectal cancer and may predict disease-free survival after preoperative radiochemotherapy and surgical resection. Strahlenther Onkol 2002;178:426-435 (Pubitemid 34847422)
10. Bache M, Holzapfel D, Kappler M, et al. Survivin protein expression and hypoxia in advanced cervical carcinoma ofpa tients treated by radiotherapy. Gynecol Oncol 2007;104:139-144 (Pubitemid 46054113)
11. Asanuma K, Kobayashi D, Furuya D, Tsuji N, Yagihashi A, Watanabe N. A role for survivin in radioresistance of pancreatic cancer cells. Jpn J Cancer Res 2002;93:1057-1062 (Pubitemid 35154273)
12. Pennati M, Binda M, Colella G, et al. Radiosensitization ofhuman melanoma cells by ribozyme-mediated inhibition ofsurvivin expression. J Invest Dermatol 2003;120:648-654 (Pubitemid 36344009)
13. Pennati M, Folini M, Zaffaroni N. Targeting survivin in cancer therapy: fulfilled promises and open questions. Carcinogenesis 2007;28:1133-1139 (Pubitemid 47062670)
14. Kami K, Doi R, Koizumi M, et al. Downregulation ofsu rvivin by siRNA diminishes radioresistance ofpancreati c cancer cells. Surgery 2005;138:299-305. (Pubitemid 41253814)
15. Cao C, Mu Y, Hallahan DE, Lu B. XIAP and survivin as therapeutic targets for radiation sensitization in preclinical models of lung cancer. Oncogene 2004;23:7047-7052 (Pubitemid 39319166)
16. Chakravarti A, Zhai GG, Zhang M, et al. Survivin enhances radiation resistance in primary human glioblastoma cells via caspase-independent mechanisms. Oncogene 2004;23:7494-7506 (Pubitemid 39389691)
17. Rodel F, Hoffmann J, Distel L, et al. Survivin as a radioresistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer. Cancer Res 2005;65:4881-4887 (Pubitemid 40740827)
18. Altieri DC. Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 2008;8:61-70.
19. Li F, Altieri DC. Transcriptional analysis ofhuman survivin gene expression. Biochem J 1999;344:305-311 (Pubitemid 30011584)
20. Li Y, Xie M, Yang J, et al. The expression ofantiap optotic protein survivin is transcriptionally upregulated by DEC1 primarily through multiple sp1 binding sites in the proximal promoter. Oncogene 2006;25:3296-3306 (Pubitemid 43846314)
21. Wu J, Ling X, Pan D, et al. Molecular mechanism ofinhibition ofsurvi vin transcription by the GC-rich sequence-selective DNA binding antitumor agent, hedamycin: evidence ofsu rvivin downregulation associated with drug sensitivity. J Biol Chem 2005;280:9745-9751 (Pubitemid 40409673)
22. Chintharlapalli S, Papineni S, Ramaiah SK, Safe S. Betulinic acid inhibits prostate cancer growth through inhibition ofspecif icity protein transcription factors. Cancer Res 2007;67:2816-2823 (Pubitemid 46548971)
23. Yao JC, Wang L, Wei D, et al. Association between expression of transcription factor Sp1 and increased vascular endothelial growth factor expression, advanced stage, and poor survival in patients with resected gastric cancer. Clin Cancer Res 2004;10:4109-4117 (Pubitemid 38812490)
24. Wang L, Wei D, Huang S, et al. Transcription factor Sp1 expression is a significant predictor of survival in human gastric cancer. Clin Cancer Res 2003;9:6371-6380 (Pubitemid 38031822)
25. Zannetti A, Del Vecchio S, Carriero MV, et al. Coordinate up-regulation ofSp1 DNA-binding activity and urokinase receptor expression in breast carcinoma. Cancer Res 2000;60:1546-1551 (Pubitemid 30183423)
26. Chiefari E, Brunetti A, Arturi F, et al. Increased expression of AP2 and Sp1 transcription factors in human thyroid tumors: a role in NIS expression regulation? BMC Cancer 2002;2:35.
27. Hosoi Y, Watanabe T, Nakagawa K, et al. Up-regulation of DNA-dependent protein kinase activity and Sp1 in colorectal cancer. Int J Oncol 2004;25:461-468
28. Morillo LE. Migraine headache. Clin Evidence 2003;10:1547-1565
29. Krymchantowski AV, Adriano M, Fernandes D. Tolfenamic acid decreases migraine recurrence when used with sumatriptan. Cephalalgia 1999;19:186-187 (Pubitemid 29202151)
30. Tokola RA. Tolfenamic acid in combination with caffeine: absorption during acute migraine. Methods Findings Exp Clin Pharmacol 1985;7:545-550 (Pubitemid 16219779)
31. Norrelund N, Christiansen LV, Plantener S. Tolfenamic acid versus paracetamol in migraine attacks. A double-blind study in general practice. Ugeskrift Laeger 1989;151:2436-2438
32. Hakkarainen H, Vapaatalo H, Gothoni G, Parantainen J. Tolfenamic acid is as effective as ergotamine during migraine attacks. Lancet 1979;2:326-328 (Pubitemid 9243777)
33. Abdelrahim M, Baker CH, Abbruzzese JL, Safe S. Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation. J Natl Cancer Inst 2006;98:855-868 (Pubitemid 43923442)
34. Liu W, Konduri SD, Bansal S, et al. Estrogen receptor-α binds p53 tumor suppressor protein directly and represses its function. J Biol Chem 2006;281:9837-9840 (Pubitemid 43864514)
35. Sayeed A, Konduri SD, Liu W, Bansal S, Li F, Das GM. Estrogen receptor a inhibits p53-mediated transcriptional repression: implications for the regulation of apoptosis. Cancer Res 2007;67:7746-7755 (Pubitemid 47281368)
36. Abdelrahim M, Baker CH, Abbruzzese JL, et al. Regulation ofvascular endothelial growth factor receptor-1 expression by specificity proteins 1, 3, and 4 in pancreatic cancer cells. Cancer Res 2007;67:3286-3294
37. Asanuma K, Moriai R, Yajima T, et al. Survivin as a radioresistance factor in pancreatic cancer. Jpn J Cancer Res 2000;91:1204-1209
38. Coma S, Noe V, Lavarino C, et al. Use ofsiRNAs and antisense oligonucleotides against survivin RNA to inhibit steps leading to tumor angiogenesis. Oligonucleotides 2004;14:100-113 (Pubitemid 38987380)
39. Tsuruma T, Hata F, Torigoe T, et al. Phase I clinical study of antiapoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer. J Transl Med 2004;2:19. (Pubitemid 39130353)
40. Ling X, Li F. Silencing ofantiap optotic survivin gene by multiple approaches ofRNA interference technology. Biotechniques 2004;36:450-4, 456-460 (Pubitemid 38299059)
41. Ning S, Fuessel S, Kotzsch M, et al. siRNA-mediated down-regulation ofsurvivin inhibits bladder cancer cell growth. Int J Oncol 2004;25:1065-1071
42. Zhong H, Bowen JP. Antiangiogenesis drug design: multiple pathways targeting tumor vasculature. Curr Med Chem 2006;13:849-862
43. Abdelrahim M, Smith R III, Burghardt R, Safe S. Role of Sp proteins in regulation of vascular endothelial growth factor expression and proliferation of pancreatic cancer cells. Cancer Res 2004;64:6740-6749 (Pubitemid 39297937)